Cybin Acquires Phase 1 DMT Study from Entheon Biomedical

Cybin Inc. (NEO: CYBN) (NYSE: CYBN) announced that the company has acquired a Phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF). This DMT study, which is the largest to date, is expected to accelerate the clinical development of CYB004, Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, by approximately nine months.

Doug Drysdale, CEO of Cybin commented on the acquisition:

“With the closing of this transaction we are well on our way to advancing CYB004 through Phase 1 development and gathering essential safety and dosing optimization data that will inform the clinical path forward for this important molecule. Cybin now has multiple clinical-stage programs ongoing that we believe will contribute significantly to a greater understanding of the potential of psychedelics to provide therapeutic relief to patients who suffer with a variety of mental health issues.”

Cybin paid CDN$1,000,000 in relation to the Acquisition. Up to an additional CDN$480,000 may be paid to Entheon for consulting services up to twelve months following the closing of the Acquisition. Cybin has also entered into a data license agreement with Entheon that permits them to access certain data to support the Entheon IQ program.

The CYB004-E study is an adaptive, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of a target-controlled intravenous infusion of DMT in healthy smokers.

Primary Objectives:

• evaluate the safety of increasing doses of a single dose continuous DMT infusion over 90 minutes.
• characterize the PK of a single dose DMT administered continuously over 90 minutes.
• characterize the PD of a single dose DMT administered continuously over 90 minutes
• establish the minimum DMT dose required to produce a psychedelic effect.

0 0 votes
Article Rating

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Notify of
Inline Feedbacks
View all comments